Mirum Pharmaceuticals (MIRM) EBT (2019 - 2026)

Mirum Pharmaceuticals' EBT history runs 8 years deep, the most recent figure standing at -$789.7 million for Q1 2026.

• In Q1 2026, EBT fell 5686.05% year-over-year to -$789.7 million; the TTM figure through Mar 2026 stood at -$797.5 million (down 950.6% YoY), while the FY2025 annual figure was -$21.4 million, up 75.35% from the prior year.
• EBT was -$789.7 million for Q1 2026 at Mirum Pharmaceuticals, down from -$5.0 million in the prior quarter.
• In the past five years, EBT ranged from a high of $2.6 million in Q3 2025 to a low of -$789.7 million in Q1 2026.
• Historically, EBT has averaged -$70.7 million across 5 years, with a median of -$24.7 million in 2024.
• The sharpest annual moves came in 2025 and 2026: EBT soared 119.03% in 2025, then slumped 5686.05% in 2026.
• A 5-year view of EBT shows it stood at -$36.3 million in 2022, then climbed by 2.36% to -$35.4 million in 2023, then soared by 31.24% to -$24.4 million in 2024, then surged by 79.63% to -$5.0 million in 2025, then sank by 15811.34% to -$789.7 million in 2026.
• The last three EBT figures came in at -$789.7 million (Q1 2026), -$5.0 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.